AUS
NZ
UK
CA
USA
IND
_06_19_2026_12_34_15_139937.jpg)
The Mesoblast Ltd (ASX:MSB) share price has sharply declined by 25% to a decade-low of 30.5 cents following the completion of another round of capital raising. As part of the ASX healthcare stocks, this biotechnology firm is confronting challenges in securing approval from the US Food and Drug Administration (FDA) for its stem cell therapies. The company has experienced ongoing cash burn in recent years, necessitating multiple capital raises to sustain its operations.
Reasons for Mesoblast Share Price Decline:
Ongoing Struggle for FDA Approval: Mesoblast has been facing challenges in securing FDA approval for its stem cell therapies. The prolonged approval process has contributed to the company's financial strain.
Continuous Need for Capital Infusion: To address its cash burn and funding requirements, ASX MSB has resorted to multiple capital raisings, impacting investor sentiment.
Discounted Placement and Entitlement Offer: Mesoblast completed an institutional placement and entitlement offer, raising $55 million at a 26% discount of $0.30 per new share. The discounted offer price has led to a sharp decline in the share price.
CEO's Commitment: Despite the discounted placement, Mesoblast highlighted that the placement was oversubscribed, and the CEO, Dr Silviu Itescu, has committed to taking up a majority of his entitlement.
Company's Response:
Dr Itescu expressed gratitude for the ongoing support from key institutional shareholders and noted that the funds raised would help Mesoblast achieve its key objectives for 2024.
Retail Entitlement Offer:
Mesoblast is set to proceed with its retail entitlement offer, aiming to raise $42 million at the same price. The success of this offer remains uncertain, given the modest discount to the current share price.
Investor Impact:
The Mesoblast share price has experienced a substantial decline of approximately 75% over the last 12 months. The continuous need for capital raising and challenges in obtaining regulatory approval have contributed to the erosion of investor confidence.
Conclusion:
Mesoblast's latest share price decline reflects the market's response to the company's ongoing financial challenges and the need for discounted capital raising. Investors will closely monitor the company's progress in addressing regulatory hurdles and achieving its outlined objectives for 2024
